Stomach cancer breakthrough: study seeks best Post-Surgery care for complete responders

NCT ID NCT07161453

Not yet recruiting Disease control Sponsor: Liaoning Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at 500 stomach cancer patients who had chemotherapy plus immunotherapy before surgery and achieved a complete response (no cancer left in the removed tissue). It compares different post-surgery treatments, including chemotherapy alone or with immunotherapy, to see which is better at preventing cancer from coming back. The goal is to find the safest and most effective follow-up plan for these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Chemotherapy (SOX or XELOX) with or without a PD-1 inhibitor (immunotherapy)
What this could lead to: If successful, this could help identify the best post-surgery treatment to prevent cancer recurrence in patients who already had a strong response to pre-surgery therapy.
What could go wrong: This is a real-world study, not a tightly controlled trial, so results may be less definitive. The treatments have side effects like fatigue, nausea, and immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.